US67022C1062 - ADR
NASDAQ:NCNA (10/4/2022, 10:29:33 AM)+0.02 (+1.96%)
|GICS Sector||Health Care|
|Earnings (Last)||08-17 2022-08-17/amc||Earnings (Next)||11-16 2022-11-16|
|Ins Owners||N/A||Inst Owners||26.58%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The firm is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. The Company’s subsidiaries include NuCana, Inc. and NuCana BioMed Trustee Company Limited.
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT
CEO: Hugh Griffith
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination...
EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical...
EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at...
Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH,...
Here you can normally see the latest stock twits on NCNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.